NDASUBCUTANEOUSINJECTABLEPriority Review
Approved
Aug 2011
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
4
Data completeness
4/8 — Partial
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FIRAZYR (icatibant acetate) is a small-molecule bradykinin B2 receptor antagonist approved in 2011 for acute treatment of hereditary angioedema (HAE) attacks in patients age 18 and older. It works by blocking bradykinin-mediated inflammation and vascular permeability, the primary driver of angioedema in HAE patients. Administered via subcutaneous injection, it provides rapid symptom relief during acute attacks.
$0.056BPart D
PeakStable
Peak-stage product with $56M annual spending and 920 claims indicates established market presence, suggesting stable brand team size and focus on market defense rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (4)
A Study of Lanadelumab (Takhzyro) and Icatibant (Firazyr®) in Persons With HAE in China
Started Jul 2024
115 enrolled
Hereditary Angioedema (HAE)
FIRAZYR General Drug Use-Results Survey (Japan)
Started Nov 2018
179 enrolled
Hereditary Angioedema (HAE)
Open-label, Single-arm Study to Assess the Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Dose of Icatibant in Healthy Japanese Volunteers
Started Feb 2014
12 enrolled
Hereditary Angioedema (HAE)
Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)
Started Jul 2009
1,761 enrolled
Hereditary Angioedema (HAE)
Career Relevance
Worked on FIRAZYR at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.